Understanding GLP-1 & Weight Management: For Long Term Success

How GLP-1 Medication support weight loss

Glucagon-like peptide-1 (GLP-1) therapies have transformed the landscape of weight management for many individuals living with obesity and/or type 2 diabetes. These medications including semaglutide and others in the same class mimic the body’s natural GLP-1 hormone to reduce appetite, slow gastric emptying, and improve blood sugar regulation. While GLP-1 medications can be powerful tools for weight loss, they are not a stand-alone solution. Meaningful, lasting results depend on comprehensive lifestyle support, especially structured nutrition interventions and personalized guidance from a Registered Dietitian Nutritionist.

Importance of Dietitians in your GLP-1 Journey

GLP-1 agonist receptor supports weight loss by influencing appetite regulation and digestion. Overall, these medications:

  • Reduce hunger and increase feelings of fullness

  • Slow gastric emptying, which enhances satiety

  • Improve blood glucose regulation

  • Reduce food cravings

Together, these effects often lead to a reduced calorie intake and significant weight loss when paired with lifestyle changes. However, medication alone does not address the behavioral, nutritional, and physiological factors that are required for long-term success.

Registered Dietitian Nutritionists, trained in Medical Nutrition Therapy, can provide individualized guidance based on health history, lifestyle, and goals. During GLP-1 therapy, Dietitians help ensure adequate intake of protein, calories, and essential micronutrients, which are important during periods of reduced appetite and rapid weight loss.

Clinical research demonstrates that GLP-1 therapies are most effective when combined with structured lifestyle interventions, including nutrition counseling. The trials leading to FDA approval of GLP-1 medications incorporated dietary guidance and physical activity support, reinforcing the importance of a thorough nutritional approach.

Nutrition Practical Tips for GLP-1

GLP-1 medications are commonly associated with gastrointestinal side effects: nausea, constipation, and early satiety. Without proper nutrition guidance, individuals may unintentionally under-eat and increase the risk of:

  • Loss of lean muscle mass

  • Inadequate protein intake

  • Micronutrient deficiencies

  • Decreased energy level

Dietitians play a critical role in helping individuals manage these side effects through proper meal timing, balanced meals, hydration, and nutrient optimization supporting both short and long-term health outcomes.

Building Sustainable Eating Habits

Weight loss is only one component of successful weight management. Maintaining weight loss requires long-term behavior and lifestyle changes along with consistent eating patterns that support overall health.

Dietitians help individuals develop sustainable habits by:

  • Teaching how to recognize hunger and fullness cues

  • Creating balanced, nutrient-dense meals

  • Planning for social situations and lifestyle challenges

  • Supporting long-term weight maintenance strategies

Research shows that without ongoing lifestyle and nutrition support weight regain can occur when GLP-1 medication is discontinued.

Conclusion

GLP-1 medications represent an advancement in weight management and can be an effective tool for supporting weight loss. However, long-term success depends on more than medication alone. Working with a Registered Dietitian Nutritionist helps individuals navigate appetite changes, meet nutrient needs, preserve muscle mass, manage side effects, and build sustainable eating habits that support lifelong health. When combined with evidence-based nutrition and lifestyle support, GLP-1 therapy can become part of a sustainable approach to weight management and not just a short-term solution.

Sources

Dariush Mozaffarian, Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Shagun Bindlish, Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Deepa Sannidhi, Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. https://doi.org/10.1002/oby.24336

Despain, D., & Hoffman, B. (2024). Optimizing Nutrition, Diet, and Lifestyle Communication in GLP-1 Medication Therapy for Weight Management: A Qualitative Research Study with Registered Dietitians. Obesity Pillars, 12, 100143. https://doi.org/10.1016/j.obpill.2024.100143

Israa Moetaz, Suhad Abumweis, Alqadi, S., & Mahmoud AbuGhoush. (2025). The Role of the Dietitian in Weight Management of Adults with Obesity without Diabetes Using Glucagon like Peptide‐1 Agonist Receptors: a Systematic Review and Meta‐Analysis of Randomized Controlled Clinical Trials. Clinical Obesity. https://doi.org/10.1111/cob.70030

Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, 122 (1). https://doi.org/10.1016/j.ajcnut.2025.04.023

Prioritizing Health | Diabetes, Diet and GLP-1 RAs - American College of Cardiology. (2025). American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Articles/2025/06/01/01/Prioritizing -Health-Diabetes-Diet-and-GLP-1-RAsutm_source=chatgpt.com

Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & Leon, J. D. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules, 15 (3), 408–408. https://doi.org/10.3390/biom15030408

Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 14(14), 1085799. https://doi.org/10.3389/fendo.2023.1085799

Kimberly Aparicio, Dietetic Intern

Alicia Calvo, MPH, RDN, CDCES, CEDRD

Next
Next

Picky Eating vs Avoidant/Restrictive Food Intake Disorder: Understanding the Difference